|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:acquisition
|
Akcea Therapeutics
|
|
gptkbp:ceo
|
Brett P. Monia
|
|
gptkbp:clinical_trial
|
Phase 1
Phase 2
Phase 3
ongoing studies
completed studies
planned studies
|
|
gptkbp:collaboration
|
gptkb:Astra_Zeneca
gptkb:Bristol-Myers_Squibb
gptkb:Biogen
gptkb:Bayer
|
|
gptkbp:collaborations
|
academic institutions
pharmaceutical companies
research organizations
|
|
gptkbp:focus
|
RNA-targeted drug discovery
|
|
gptkbp:founded
|
gptkb:1989
|
|
gptkbp:founder
|
gptkb:Stanley_T._Crooke
|
|
gptkbp:headquarters
|
gptkb:Carlsbad,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ionis Pharmaceuticals
|
|
gptkbp:invention
|
RNA-targeted therapies
|
|
gptkbp:investment
|
clinical trials
drug development
biotechnology research
innovation in medicine
|
|
gptkbp:leadership
|
gptkb:CEO
gptkb:Board_of_Directors
|
|
gptkbp:number_of_employees
|
~500
|
|
gptkbp:partnership
|
gptkb:GSK
gptkb:Sanofi
gptkb:Regeneron_Pharmaceuticals
gptkb:Novartis
Ionis and Biogen
|
|
gptkbp:product
|
gptkb:Spinraza
Waylivra
Tegsedi
|
|
gptkbp:research_areas
|
cardiology
metabolic disorders
neurology
oncology
rare diseases
autoimmune diseases
cardiovascular diseases
infectious diseases
neuromuscular diseases
metabolic diseases
|
|
gptkbp:research_focus
|
gptkb:Oncology
genetic disorders
autoimmune diseases
infectious diseases
|
|
gptkbp:revenue
|
$300 million (2020)
|
|
gptkbp:stock_exchange
|
gptkb:NASDAQ
|
|
gptkbp:stock_symbol
|
IONS
|
|
gptkbp:technology
|
antisense oligonucleotide
|
|
gptkbp:website
|
www.ionispharma.com
|
|
gptkbp:bfsParent
|
gptkb:Biogen
|
|
gptkbp:bfsLayer
|
4
|